Wells Fargo analyst Derek Archila upgraded Celldex to Equal Weight from Underweight with an unchanged price target of $27. The analyst cites valuation for the upgrade. Celldex’s risk/reward is now more balanced, but upside is limited amid few catalysts, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CLDX:
- Biotech Alert: Searches spiking for these stocks today
- Celldex 7.43M share Spot Secondary priced at $27.00
- Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
- Celldex Therapeutics Announces Proposed Public Offering of Common Stock
- Celldex announces common stock offering, no amount given